Vorasidenib

Major

Vorasidenib Clindamycin ANTIROBE Explained Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Vorasidenib Colchicine Colcrys Explained Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Vorasidenib Abemaciclib Verzenio Explained Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Vorasidenib Acalabrutinib Calquence Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Vorasidenib Axitinib Inlyta Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Vorasidenib Bosutinib Bosulif Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Vorasidenib Brigatinib Alunbrig Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Vorasidenib Capmatinib Tabrecta Increased vorasidenib exposure and an increased risk of vorasidenib-related adverse reactions Details Vorasidenib Clindamycin Injection ANTIROBE Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Vorasidenib Clindamycin Topical C/T/S® Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Vorasidenib Clindamycin Vaginal Cleocin Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Vorasidenib Cobimetinib Cotellic Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Vorasidenib Cyclosporine Injection Atopica Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Vorasidenib Cyclosporine Ophthalmic Cequa Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Vorasidenib Dasatinib Phyrago Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Vorasidenib Dihydroergotamine Injection DHE-45® Injection Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Vorasidenib Dihydroergotamine Nasal Spray Migranal Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Vorasidenib Docetaxel Beizray Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Vorasidenib Docetaxel Injection Beizray Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Vorasidenib Dofetilide Tikosyn Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Vorasidenib Enasidenib Idhifa Increased vorasidenib exposure and an increased risk of vorasidenib-related adverse reactions Details Vorasidenib Entrectinib Rozlytrek Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Vorasidenib Estradiol Delestrogen Increased vorasidenib exposure, an increased risk of vorasidenib-related adverse reactions, reduced hormonal contraceptive exposur... Details Vorasidenib Estradiol Topical Divigel Increased vorasidenib exposure, an increased risk of vorasidenib-related adverse reactions, reduced hormonal contraceptive exposur... Details Vorasidenib Estradiol Transdermal Patch Alora® Increased vorasidenib exposure, an increased risk of vorasidenib-related adverse reactions, reduced hormonal contraceptive exposur... Details Vorasidenib Everolimus Afinitor Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Vorasidenib Fentanyl Transdermal Patch Duragesic® Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Vorasidenib Interferon Alfa-2B Injection Intron A® Increased vorasidenib exposure and an increased risk of vorasidenib-related adverse reactions Details Vorasidenib Levonorgestrel After banger Increased vorasidenib exposure, an increased risk of vorasidenib-related adverse reactions, reduced hormonal contraceptive exposur... Details Vorasidenib Levonorgestrel Intrauterine System Kyleena Increased vorasidenib exposure, an increased risk of vorasidenib-related adverse reactions, reduced hormonal contraceptive exposur... Details Vorasidenib Medroxyprogesterone Amen® Increased vorasidenib exposure, an increased risk of vorasidenib-related adverse reactions, reduced hormonal contraceptive exposur... Details Vorasidenib Medroxyprogesterone Injection Depo-Provera Increased vorasidenib exposure, an increased risk of vorasidenib-related adverse reactions, reduced hormonal contraceptive exposur... Details Vorasidenib Mexiletine Mexitil® Increased vorasidenib exposure and an increased risk of vorasidenib-related adverse reactions Details Vorasidenib Midostaurin Rydapt Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Vorasidenib Montelukast Singulair Reduced vorasidenib exposure and reduced anti-tumor activity of vorasidenib Details Vorasidenib Neratinib Nerlynx Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Vorasidenib Olaparib Lynparza Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details